Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine

Novel Vaccine Focused On T-Cell Immunity

Executive Summary

In search of a differentiated approach, ImmunityBio’s candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.

You may also be interested in...



To Boost Or Not To Boost? Pfizer At Odds With US FDA

US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.

Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B

Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.

Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question

Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel